New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
16:05 EDTAMGN, BINDBIND Therapeutics, Amgen will not exercise development option
BIND Therapeutics (BIND) announce the completion of its collaborative research program with Amgen (AMGN) originally entered into in January 2013. Amgen and BIND have notified each other that they will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload. “The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen. Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued,” said Scott Minick, Chief Executive Officer of BIND Therapeutics. “We remain focused on the continued development of our Accurin platform, including our proprietary drug candidate, BIND-014, and our collaborations with AstraZeneca and Pfizer, as well as our recently announced research collaboration with Roche. Furthermore, consistent with our previous guidance, we continue to expect that our cash, cash equivalents and short-term investments, and research development funding that we expect to receive under our existing collaborations, excluding any potential milestone payments, will fund our operating expenses and capital expenditure requirements through at least mid-2015.”
News For BIND;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
14:42 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
March 30, 2015
09:02 EDTAMGNAmgen says FDA grants priority review for Kyprolis sNDA
Subscribe for More Information
March 26, 2015
06:45 EDTAMGNBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 24, 2015
09:10 EDTAMGNDako announces collaboration agreement with Amgen
Dako, an Agilent Technologies (A) company, announced a new Master Collaboration Agreement with Amgen (AMGN). The expanded collaboration will allow both companies to benefit from knowledge-sharing within the field of drug-diagnostic research and development in general, and in relation to companion diagnostic products in particular. The financial details of the agreement were not disclosed.
March 23, 2015
12:10 EDTAMGNTeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:03 EDTAMGNLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 20, 2015
09:06 EDTAMGNAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information
07:41 EDTAMGNAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTAMGNAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTAMGNAmgen denied preliminary injunction for biologics against Novartis, Reuters says

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use